BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 28681349)

  • 21. Recurrent Glioblastoma: From Molecular Landscape to New Treatment Perspectives.
    Birzu C; French P; Caccese M; Cerretti G; Idbaih A; Zagonel V; Lombardi G
    Cancers (Basel); 2020 Dec; 13(1):. PubMed ID: 33375286
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Role of Checkpoint Inhibitors in Glioblastoma.
    Desai K; Hubben A; Ahluwalia M
    Target Oncol; 2019 Aug; 14(4):375-394. PubMed ID: 31290002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patupilone (epothilone B) for recurrent glioblastoma: clinical outcome and translational analysis of a single-institution phase I/II trial.
    Oehler C; Frei K; Rushing EJ; McSheehy PM; Weber D; Allegrini PR; Weniger D; Lütolf UM; Knuth A; Yonekawa Y; Barath K; Broggini-Tenzer A; Pruschy M; Hofer S
    Oncology; 2012; 83(1):1-9. PubMed ID: 22688083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Association of radiotherapy and chemotherapy-targeted therapies in glioblastomas].
    Laigle-Donadey F; Dehais C; Mazeron JJ; Sanson M
    Bull Cancer; 2009 Mar; 96(3):291-7. PubMed ID: 19318307
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Glioblastoma targeted therapy: updated approaches from recent biological insights.
    Touat M; Idbaih A; Sanson M; Ligon KL
    Ann Oncol; 2017 Jul; 28(7):1457-1472. PubMed ID: 28863449
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recurrent glioblastomas in the elderly after maximal first-line treatment: does preserved overall condition warrant a maximal second-line treatment?
    Zanello M; Roux A; Ursu R; Peeters S; Bauchet L; Noel G; Guyotat J; Le Reste PJ; Faillot T; Litre F; Desse N; Emery E; Petit A; Peltier J; Voirin J; Caire F; Barat JL; Vignes JR; Menei P; Langlois O; Dezamis E; Carpentier A; Dam Hieu P; Metellus P; Pallud J;
    J Neurooncol; 2017 Nov; 135(2):285-297. PubMed ID: 28726173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-operative management of primary glioblastoma multiforme in patients over 60 years of age.
    Daróczi B; Szántó E; Tóth J; Barzó P; Bognár L; Bakó G; Szántó J; Mózes P; Hideghéty K
    Ideggyogy Sz; 2013 Nov; 66(11-12):391-8. PubMed ID: 24555238
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Glioblastoma multiforme: a glance at advanced therapies based on nanotechnology.
    Rezaei V; Rabiee A; Khademi F
    J Chemother; 2020 May; 32(3):107-117. PubMed ID: 31984871
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What next for newly diagnosed glioblastoma?
    Domingo-Musibay E; Galanis E
    Future Oncol; 2015; 11(24):3273-83. PubMed ID: 26558493
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current and Future Drug Treatments for Glioblastomas.
    Ohba S; Hirose Y
    Curr Med Chem; 2016; 23(38):4309-4316. PubMed ID: 27758718
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Temozolomide in radio-chemotherapy combined treatment for newly-diagnosed glioblastoma multiforme: phase II clinical trial.
    Lanzetta G; Campanella C; Rozzi A; Nappa M; Costa A; Fedele F; Innocenzi G; Gagliardi FM; Salvati M; Minniti G; Frati A; Frati L; Vecchione A
    Anticancer Res; 2003; 23(6D):5159-64. PubMed ID: 14981983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Emerging therapies for glioblastoma.
    Thomas AA; Brennan CW; DeAngelis LM; Omuro AM
    JAMA Neurol; 2014 Nov; 71(11):1437-44. PubMed ID: 25244650
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Glioblastoma treatment in 2010].
    Djedid R; Tomasi O; Haidara A; Rynkowski M; Lefranc F
    Rev Med Brux; 2009; 30(5):496-505. PubMed ID: 19998795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Concomitant radiotherapy with chemotherapy in patients with glioblastoma].
    Benouaich-Amiel A; Simon JM; Delattre JY
    Bull Cancer; 2005 Dec; 92(12):1065-72. PubMed ID: 16396752
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanisms of disease: temozolomide and glioblastoma--look to the future.
    Mrugala MM; Chamberlain MC
    Nat Clin Pract Oncol; 2008 Aug; 5(8):476-86. PubMed ID: 18542116
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
    Lefranc F; Rynkowski M; DeWitte O; Kiss R
    Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overcoming the blood-brain tumor barrier for effective glioblastoma treatment.
    van Tellingen O; Yetkin-Arik B; de Gooijer MC; Wesseling P; Wurdinger T; de Vries HE
    Drug Resist Updat; 2015 Mar; 19():1-12. PubMed ID: 25791797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [What's next in glioblastoma treatment: Tumor-targeted or immune-targeted therapies?].
    Schernberg A; Marabelle A; Massard C; Armand JP; Dumont S; Deutsch E; Dhermain F
    Bull Cancer; 2016 May; 103(5):484-98. PubMed ID: 27032303
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.
    Stupp R; Dietrich PY; Ostermann Kraljevic S; Pica A; Maillard I; Maeder P; Meuli R; Janzer R; Pizzolato G; Miralbell R; Porchet F; Regli L; de Tribolet N; Mirimanoff RO; Leyvraz S
    J Clin Oncol; 2002 Mar; 20(5):1375-82. PubMed ID: 11870182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.